Compare RCMT & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | CNTB |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 157.1M |
| IPO Year | N/A | 2021 |
| Metric | RCMT | CNTB |
|---|---|---|
| Price | $20.97 | $2.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $8.50 |
| AVG Volume (30 Days) | 45.6K | ★ 502.0K |
| Earning Date | 11-05-2025 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $309,840,000.00 | $762,000.00 |
| Revenue This Year | $15.20 | N/A |
| Revenue Next Year | $7.50 | $38,289.22 |
| P/E Ratio | $12.25 | ★ N/A |
| Revenue Growth | ★ 13.70 | N/A |
| 52 Week Low | $13.18 | $0.51 |
| 52 Week High | $28.27 | $3.28 |
| Indicator | RCMT | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 49.63 |
| Support Level | $20.59 | $2.27 |
| Resistance Level | $21.58 | $2.56 |
| Average True Range (ATR) | 0.74 | 0.18 |
| MACD | 0.30 | -0.07 |
| Stochastic Oscillator | 78.45 | 16.13 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.